Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Li, Jie ^a,b   Liu, Junfeng ^b   Liu, Ming ^b   Zhang, Shihong ^b   Hao, Zilong ^b   Zhang, Jing ^c   Zhang, Canfei ^d  

^a People s Hospital of Deyang City   (China)

^b SICHUAN UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ADVERSE EVENT; AGE; ALL CAUSE MORTALITY; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; GENDER; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICAL HISTORY; META ANALYSIS; PATENT FORAMEN OVALE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THERAPY; TIME TO EVENT ANALYSIS; TRANSCATHETER DEVICE CLOSURE; TRANSIENT ISCHEMIC ATTACK; ADULT; COMPLICATION; FEMALE; FORAMEN OVALE, PATENT; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROCEDURES; RISK ASSESSMENT; SEPTAL OCCLUDER; STROKE;

ADULT; ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; FORAMEN OVALE, PATENT; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; SECONDARY PREVENTION; SEPTAL OCCLUDER DEVICE; STROKE;

EID: 84989955398     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009938.pub2     Document Type: Review

References (65)

1. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine 2012;366(11):991-9.
2. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine 2013;368(12):1083-91.
3. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine 2013;368(12):1092-100.
4. Mooney MR. CARDIA STAR trial: a United States randomized clinical trial of the CARDIA STAR patent foramen ovale closure system. http://www.mplsheart.com/pages/Research.asp?ID=10&SID=28 (accessed by the Cochrane Stroke Group 2006).
5. Hansen CS, Tonder N, Iversen KK. The effect of device closure of patent foramen ovale in elderly patients with cryptogenic stroke/TCI. ClinicalTrials.gov (http://www. ClinicalTrials.gov) 2009.
6. Rosin L, Berger F. PEPSIS: Paraoxial Embolism Prevention Study in Ischemic Stroke. PEPSIS Trial Website (http://www.pepsis.stroke-trial.com) (accessed by the Cochrane Stroke Group 2002).
7. Mas JL. Patent foramen ovale closure or anticoagulants versus antiplatelet therapy to prevent stroke recurrence (CLOSE). ClinicalTrials.gov (http://www. ClinicalTrials.gov) 2007.
8. Song JK, Lee JY. Device closure versus medical therapy for cryptogenic stroke patients with high-risk patent foramen ovale (DEFENSE-PFO). ClinicalTrials.gov (http://www. ClinicalTrials.gov) 2012.
9. Kasner SE, Rhodes JF, Sondergaard L, Thomassen L. GORE HELEX septal occluder for patent foramen ovale (PFO) closure in stroke patients (Gore REDUCE). ClinicalTrials.gov (http://www. ClinicalTrials.gov) 2008.
10. Adams HP, Bendixen BH, Kappelle J, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24(1):35-41.
11. Agarwal S, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovascular Interventions 2012;5(7):777-89.
12. Alameddine F, Block PC. Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: acute results from the FORECAST registry. Catheterization and Cardiovascular Interventions 2004;62(4):512-6.
13. AlmekhlafiMA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology 2009;73(2):89-97.
14. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?. Stroke 2009;40(7):2349-55.
15. Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: periprocedural safety and mid-term follow-up results of three different device occluder systems. European Heart Journal 2004;25(5):424-30.
16. Capodanno D, Milazzo G, Vitale L, Di Stefano D, Di Salvo M, Grasso C, et al. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2, 303 patients from three randomised trials and 2, 231 patients from 11 observational studies. EuroIntervention 2014;9(11):1342-9.
17. Carpenter DA, Ford AL, Lee JM. Patent foramen ovale and stroke: should PFOs be closed in otherwise cryptogenic stroke?. Current Atherosclerosis Reports 2010;12(4):251-8. [DOI:]
18. Davis D, Gregson J, Willeit P, Stephan B, Al-Shahi Salman R, Brayne C. Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta-analysis of association studies. Neuroepidemiology 2013;40(1):56-67.
19. De Cillis E, Basile DP, Acquaviva T, De Blasi R, Petruzzellis M, Bortone AS. Abstract 8807: Efficacy and effectiveness evaluation of secondary prevention of cryptogenic stroke or TIA in patients with PFO successfully treated by percutaneous approach: six years follow-up. Circulation 2010; Vol. 122:A8807.
20. Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. Journal of the American College of Cardiology 2007;49(7):797-802.
21. Di Tullio MR, Homma S. Patent foramen ovale and stroke: what should be done?. Current Opinion in Hematology 2009;16(5):391-6.
22. Di Tullio MR. Patent foramen ovale: echocardiographic detection and clinical relevance in stroke. Journal of the American Society of Echocardiography 2010;23(2):144-55.
23. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371(9624):1612-23.
24. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
25. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-76. [DOI:]
26. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Study design of the CLOSURE I trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex Septal Closure System versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke 2010;41:2872-83.
27. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment subtypes of ischemic stroke: the German stroke data bank. Stroke 2001;32(11):2559-66.
28. Hakeem A, Marmagkiolis K, Hacioglu Y, Uretsky BF, Gundogdu B, Leesar M, et al. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: comprehensive systematic review and meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine 2013;14(6):349-55.
29. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
30. Hong TE, Thaler D, Brorson J. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the US multicenter clinical trial. Catheterization and Cardiovascular Interventions 2003;60(4):524-8.
31. Hornung M, Bertog SC, Franke J, Id D, Taaffe M, Wunderlich N, et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. European Heart Journal 2013;34(43):3362-9.
32. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli. Annals of Internal Medicine 2003;139(9):753-60.
33. Khan AR, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic Stroke. Journal of the American College of Cardiology 2013;6(12):1316-23.
34. Kitsios GD, Thaler DE, Kent DM. Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials. Stroke 2013;44(9):2640-3.
35. Ko R, Walker NE, Mullen MJ. Different patent foramen ovale closure techniques in varying anatomies. Interventional Cardiology 2010;2(1):85-95.
36. Kwong JSW, Lam Y-Y, Yu C-M. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials. International Journal of Cardiology 2013;168(4):4132-8.
37. Lee BC, Hwang SH, Jung S, Yu KH, Lee JH, Cho SJ, et al. The Hallym Stroke Registry: a web-based stroke data bank with an analysis of 1, 654 consecutive patients with acute stroke. European Neurology 2005;54(2):81-7.
38. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurology 2007;6(5):456-64.
39. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119(3):e21-181.
40. Maron BA, Shekar PS, Goldhaber SZ. Paradoxical embolism. Circulation 2010;122(19):1968-72.
41. Mattle HP, Meier B, Nedeltchev K. Prevention of stroke in patients with patent foramen ovale. International Journal of Stroke 2010;5(2):92-102.
42. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. Journal of the American College of Cardiology 2006;47(2):440-5.
43. Nagaraja V, Raval J, Eslick GD, Burgess D, Denniss AR. Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta-analysis of randomised trials. Heart, Lung and Circulation 2013;22(11):903-9.
44. Ntaios G, Papavasileiou V, Makaritsis K, Michel P. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis. International Journal of Cardiology 2013;169(2):101-5.
45. O'Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trial. Journal of the American College of Cardiology 2009;53(21):2014-8.
46. Orgera MA, O'Malley PG, Taylor AJ. Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and meta-analysis. Southern Medical Journal 2001;94(7):699-703.
47. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000;55(8):1172-9.
48. Paciaroni M, Agnelli G, Bertolini A, Pezzini A, Padovani A, Caso V, et al. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovascular Diseases 2010;31(2):109-16.
49. Pandit A, Aryal MR, Pandit AA, Jalota L, Kantharajpur S, Hakim FA, et al. PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta-analysis of randomised trials. Heart, Lung and Circulation 2014;23(4):303-8.
50. Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes. A population-based study of incidence and risk factor. Stroke 1999;30(12):2513-6.
51. Pickett C, Villines T, Ferguson M, Hulten E. Cost analysis of percutaneous closure versus medical therapy for cryptogenic stroke patients with a patent foramen ovale. 37th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions', SCAI 2014 Las Vegas, NV United States. 2014. [EMBASE: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=71512311]
52. Pineda AM, Nascimento FO, Yang SC, Kirtane AJ, Sommer RJ, Beohar N. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheterization and Cardiovascular 2013;82(6):968-75.
53. Rengifo-Moreno P, Palacios IF, Junpaparp P, Witzke CF, Morris LD, Romero-Corral A. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal 2013;34(43):3342-52.
54. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
55. Riaz IB, Dhoble A, Mizyed A, Hsu CH, Husnain M, Lee JZ, et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials. BMC Cardiovascular Disorders 2013;13:116.
56. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Annals of Neurology 1989;25(4):382-90.
57. Spencer FA, Lopes LC, Kennedy SA, Guyatt G. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open 2014;4:e004282. [DOI:]
58. Taaffe M, Fischer E, Baranowski A, Majunke N, Heinisch C, Leetz M, et al. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer® versus CardioSEAL®-STARflex® versus HELEX® occluder). American Journal of Cardiology 2008;101(9):1353-8.
59. Tamayo A, Harrer JU. Patent foramen ovale and ischemic stroke recurrence: the end of a never-ending story?. Neurology 2009;73(2):84-5.
60. Thaler DE, Kent DM. Rethinking trial strategies for stroke and patent foramen ovale. Current Opinion in Neurology 2010;23(1):73-8.
61. Udell JA, Opotowsky AR, Khairy P, Silversides CK, Gladstone DJ, O'Gara PT, et al. Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses. Canadian Journal of Cardiology 2014; Vol. 30, issue 10:1216-24.
62. Weimar C, Holle DN, Benemann J, Schmid E, Schminke U, Haberl RL, et al. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovascular Diseases 2009;28(4):349-56.
63. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. Journal of the American College of Cardiology 2004;44(4):750-8.
64. Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, DiNicolantonio JJ, Lansky AJ, et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart 2014;100(5):389-95.
65. Wöhrle J. Closure of patent foramen ovale after cryptogenic stroke. Lancet 2006;368(9533):350-2. [DOI:]